QuickPharma

17/12/2023

20/08/2021

Reminders:

19/08/2021

নোটিস:
এখন থেকে 18 বছর বা তদূর্ধ্ব ছাত্র-ছাত্রীরা https://surokkha.gov.bd/enroll এই ওয়েবসাইট এর মাধ্যমে ভ্যাক্সিন রেজিস্ট্রেশন করতে পারবেন।
যাদের NID নেই ,তারা নির্বাচন কমিশনে যোগাযোগ করতে পারেন।

-
QuickPharma
Medicine at your doorstep

19/08/2021

❤️

18/08/2021

17/08/2021

Mental health should be your first priority.

-QuickPharma
Medicine at your doorstep

17/08/2021

Vaccine co-production: Govt deal with Sinopharm, Incepta Monday

Health Minister Zahid Maleque on Sunday said, “We are making a deal with China to get access to more vaccines"

17/08/2020

Treatment approved for heavy menstrual bleeding associated with fibroids
Maria G. Tanzi

Oriahnn (AbbVie) is the first and only FDA-approved oral treatment for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The treatment is a combination capsule containing elagolix 300 mg, estradiol 1 mg, and norethindrone 0.5 mg for the morning dose copackaged with a capsule of elagolix 300 mg for the evening dose.
Uterine fibroids, common benign tumors in premenopausal women, can have a significant impact on quality of life, with symptoms such as heavy menstrual bleeding, pain, and bowel and bladder issues. Treatment options have included various surgical procedures such as hysterectomy and myomectomy, and medical therapies to reduce heavy menstrual bleeding (e.g., hormonal contraceptives, tranexamic acid, and NSAIDs).
“Although surgical treatments, such as hysterectomy, are available, patients may not qualify for surgery or want the procedure,” said Christine P. Nguyen, MD, acting director, division of Urology, Obstetrics and Gynecology in FDA’s Center for Drug Evaluation and Research in an FDA news release.
She noted that “various non-surgical therapies are used to treat fibroid-related heavy menstrual bleeding, but none have been FDA-approved specifically for this use.” The approval of Oriahnn now offers patients a nonsurgical option to help manage their condition.